Reimbursement for Medicare Part B Drugs
ASRS is advocating for:
- Fair and adequate reimbursement for Part B drugs
- Removal of the cost of Part B drugs from Physician Compare and other value/comparison tools until apples to apples comparisons can be made
Fair Reimbursement for Part B Drugs Should not Penalize Physicians or Reduce Patient Access
As pressure builds among patients, Congress and the Administration to reign in the cost of prescription drugs under the Medicare Program, physicians continue to get caught in the crossfire. Instead of regulating drug prices, policymakers continue to take aim at Part B reimbursement with proposals to change the payment formula. ASRS is actively advocating to ensure fair reimbursement for Part B drugs for ASRS members thereby preserving patients access to sight- saving drugs administered by retina specialists.
Medicare Part B covers routine medications provided in a physician office or administered in an outpatient setting. Medicare reimburses physicians the average sales price (ASP) of the drug plus an additional 6%. This “add-on” percentage is intended to cover costs associated with procuring, storing, administering, tracking, and obtaining reimbursement for Part B drugs and does not constitute profit. Unfortunately, since Congress instituted across-the-board budget sequestration cuts in 2013, the “add-on” is currently only 4.2%. According to a 2016 ASRS study conducted by Quorum [link], many members, particularly those in small practices and in rural settings, struggle to cover these costs.
ASRS actively opposes policies that would make it more difficult for physicians to administer Part B drugs. In order for physicians to be able to continue to purchase Part B drugs on behalf of their patients, the payment rate must at least cover all overhead costs. If not, patients will be forced to travel to the more expensive hospital outpatient departments to receive monthly treatments.
Base Payment Model on Real-World Cost Data
As proposals emerge for alternative payment structures, the ASRS continues to call for real-world cost data to provide an accurate framework on which to build a truly successful payment model. ASRS presented its Quorum study data (see appendix) to CMS and successfully derailed, along with the AMA and various medical specialties, a proposed CMS demonstration project that would have further cut reimbursement. The Society will continue to support data driven approaches with appropriate incentives to ensure the best clinical care using the most effective drugs. A successful alternative payment system must:
- Provide providers incentive to maximize health outcomes and value while reducing costs;
- Ensure that payment policies do not compromise quality of care or limit patients’ treatment options;
- Assess the impact of such payment policies on low-income patients; and
- Implement a sufficiently transparent and adequate exceptions process to allow providers to prescribe more-expensive products when medically necessary.
Cost Comparisons Must be Accurate or Eliminated
Since clinical response in individual patients varies among the 3 most commonly used Part B drugs for retinal diseases (i.e., anti-VEGF agents), ASRS opposes cost comparison policies that provide incentives to prescribe the lowest cost drugs without regard for the most appropriate treatment and patient preferences. Retina specialists must be able to utilize clinical judgment and consider the patient’s response to a particular drug when selecting the best course of therapy even if that causes them to prescribe the more expensive FDA approved drug. Until these incentives are accounted for or apples to apples comparisons can be made, ASRS is opposed including costs of Part B drugs in any cost assessment or comparison such as Physician Compare.
Retina specialists who buy and bill CMS for expensive injectable medications appear to spend more than retina specialists in academic settings where the reimbursement for drugs is returned to the hospital that purchased the drug even though the physicians may prescribe and administer the same amount. Therefore, meaningful costs comparisons among retina specialists cannot be made. Moreover, Physician Compare does not provide granularity at the subspecialist level to distinguish all retina specialists from ophthalmologists.
There must be appropriate peer comparisons, including at the specialty and subspecialty levels, of services provided and billed, to assess individual provider quality and cost prior to publishing such comparisons for patients. Absent apples to apples comparisons, the data is not truly meaningful to patients and in fact, may be harmful, not only for the physicians, but also for patients who are forced to make decisions that are based upon inaccurate or meaningless data.
- ASRS, Retina Society, Macula Society Letter to CMS -- December 2018
- ASRS and the Retina and Macula Societies submitted feedback on CMS' proposed Competitive Acquisition Program (CAP) for Part B Drugs and Biologicals -- Sept 2018
- ASRS Comment Letter to CMS on Quality Payment Program (QPP) -- August 2017
- Refinement Panel Sign-on Letter -- August 2016
- ASRS Comment Letter on Medicare Part B Demo Project -- June 2016
- ASRS CMS Comment Letter on Medicare Part B Payment Model -- May 2016
ASRS Comment Letter to MedPAC on Payment Strategies -- December 2014
- We Need Your Avastin Invoices -- June 20, 2019
- We Need Your Avastin Invoices to Fight for Higher Reimbursement -- June 12, 2019
- ASRS Joins AMA, AAO and other Specialties to Protect Access to Medicare Part B Drugs Nov 22, 2017
- What's Next for the Medicare Part B Demonstration Project? - Oct 5, 2016
- ASRS Offers Comment for Senate Finance Committee Hearing on Part B Demo - Jun 29, 2016
- House Energy & Commerce Committee Hearing Blasts Medicare Part B Demo - May 18, 2016
- ASRS Submits Comment Letter Opposing Part B Demo Project - May 10, 2016
- ASRS Continues Strong Opposition to Mandatory Medicare Part B Drug Demo Project: Here's How You Can Help - May 2, 2016
- Coming Soon: ASRS-Developed Cost Calculator to Help You Determine How Medicare Part B Demo Project Will Impact Your Practice - Apr 13, 2016
- Call to Action Defend Against Attack on Patient Choice: Encourage Patient Groups to Sign-on in Opposition to Flawed Medicare Part B Demo Project- Apr 7, 2016
- Call to Action! Tell Congress: CMS Must Protect Patient Choice by Revising Fatally-Flawed Payment Model - Apr 6, 2016
- Help ASRS Prepare its Response to CMS on the Part B Drug Demo Project - Mar 16, 2016
- ASRS Writes Letter to MedPAC on Potential New Payment Policies That Could Affect Retina Specialists - Dec 10, 2014